Martin Haslanger

From 2007 to 2014, Marty served as the CEO leading the company through the discovery of several novel compounds and identification of several potential therapeutic targets for future development. Prior to Apexian, Marty founded Amphora Discovery Corporation in September 2001. As President, CEO, he built the company to be a unique discovery engine with multiple projects at the IND-enabling stage. He then served in the Vice Chairman role from January of 2005 until January 2007.

Marty has three decades of pharmaceutical and biotechnology industry experience. Among those were nine years at Eli Lilly from 1992 to 2001, where he served as Executive Director of Research Technologies and President of Sphinx Labs.

Prior to that, he was Director of Cardiovascular and CNS Medicinal Chemistry at the Schering-Plough Research Institute. He began his pharmaceutical career at the Squibb Institute for Medical Research in Princeton, N.J. He led multiple projects from idea to clinical candidate stage at both Squibb and Schering-Plough.

Marty received his Ph.D. in Organic Chemistry at the University of Michigan and completed a postdoctoral fellowship at Harvard University.